Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $94000.0.

  • Utah Medical Products' Share-based Compensation rose 7735.85% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $334000.0, marking a year-over-year increase of 3046.88%. This contributed to the annual value of $256000.0 for FY2024, which is 1377.78% up from last year.
  • Utah Medical Products' Share-based Compensation amounted to $94000.0 in Q3 2025, which was up 7735.85% from $86000.0 recorded in Q2 2025.
  • Utah Medical Products' 5-year Share-based Compensation high stood at $94000.0 for Q3 2025, and its period low was $38000.0 during Q3 2022.
  • In the last 5 years, Utah Medical Products' Share-based Compensation had a median value of $52000.0 in 2024 and averaged $57473.7.
  • The largest annual percentage gain for Utah Medical Products' Share-based Compensation in the last 5 years was 7826.09% (2021), contrasted with its biggest fall of 1632.65% (2021).
  • Utah Medical Products' Share-based Compensation (Quarter) stood at $43000.0 in 2021, then skyrocketed by 44.19% to $62000.0 in 2022, then increased by 16.13% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then soared by 30.56% to $94000.0 in 2025.
  • Its Share-based Compensation was $94000.0 in Q3 2025, compared to $86000.0 in Q2 2025 and $82000.0 in Q1 2025.